Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and
fatiguability of skeletal muscles. It is an antibody-mediated disease, caused by …

Autoimmune diseases (AID) are increasingly prevalent conditions which comprise more
than 100 distinct clinical entities that are responsible for a great disease burden worldwide …

Muscle weakness and fatigue are the hallmarks of autoimmune neuromuscular junction
disorders. Although a plethora of immunosuppressive treatments exist, no cure is available …

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction (NMJ).
Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor …

Introduction Several patients with myasthenia gravis (MG) do not adequately respond to
available drugs or exhibit poor tolerance, necessitating the need for new therapies. Areas …

Antibodies of IgG4 subclass are exceptional players of the immune system, as they are
considered to be immunologically inert and functionally monovalent, and as such may be …

Myasthenia gravis (MG) is a prototypical autoantibody mediated disease. The
autoantibodies in MG target structures within the neuromuscular junction (NMJ), thus …

Myasthenia gravis with antibodies to the muscle‐specific tyrosine kinase (MuSK+ MG) is a
rare disease with distinctive pathogenic mechanisms and clinical features. An acute onset …

Myasthenia gravis (MG) is the most common autoimmune disorder affecting the
neuromuscular junction, characterized by skeletal muscle weakness and fatigability. It is …

IgG4 autoimmune diseases are characterized by the presence of antigen-specific
autoantibodies of the IgG4 subclass and contain well-characterized diseases such as …